CA2679986C - Epha3 antibodies for the treatment of solid tumors - Google Patents

Epha3 antibodies for the treatment of solid tumors Download PDF

Info

Publication number
CA2679986C
CA2679986C CA2679986A CA2679986A CA2679986C CA 2679986 C CA2679986 C CA 2679986C CA 2679986 A CA2679986 A CA 2679986A CA 2679986 A CA2679986 A CA 2679986A CA 2679986 C CA2679986 C CA 2679986C
Authority
CA
Canada
Prior art keywords
epha3
antibody
seq
region
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2679986A
Other languages
English (en)
French (fr)
Other versions
CA2679986A1 (en
Inventor
Martin Lackmann
Andrew Mark Scott
Christopher R. Bebbington
Geoffrey T. Yarranton
Carmelina Murone
Catherine To
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Ludwig Institute for Cancer Research New York
Humanigen Inc
Original Assignee
Monash University
Ludwig Institute for Cancer Research New York
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University, Ludwig Institute for Cancer Research New York, Kalobios Pharmaceuticals Inc filed Critical Monash University
Publication of CA2679986A1 publication Critical patent/CA2679986A1/en
Application granted granted Critical
Publication of CA2679986C publication Critical patent/CA2679986C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2679986A 2007-03-08 2008-03-10 Epha3 antibodies for the treatment of solid tumors Active CA2679986C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89384807P 2007-03-08 2007-03-08
US60/893,848 2007-03-08
PCT/US2008/003149 WO2008112192A2 (en) 2007-03-08 2008-03-10 Epha3 antibodies for the treatment of solid tumors

Publications (2)

Publication Number Publication Date
CA2679986A1 CA2679986A1 (en) 2008-09-18
CA2679986C true CA2679986C (en) 2018-03-06

Family

ID=39689392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2679986A Active CA2679986C (en) 2007-03-08 2008-03-10 Epha3 antibodies for the treatment of solid tumors

Country Status (13)

Country Link
US (1) US8637016B2 (enExample)
EP (2) EP3199180B1 (enExample)
JP (1) JP5311060B2 (enExample)
CN (1) CN101641115B (enExample)
AU (1) AU2008226905C1 (enExample)
CA (1) CA2679986C (enExample)
DK (1) DK3199180T3 (enExample)
ES (1) ES2910298T3 (enExample)
IL (1) IL200764A (enExample)
NZ (1) NZ579478A (enExample)
PL (1) PL3199180T3 (enExample)
PT (1) PT3199180T (enExample)
WO (1) WO2008112192A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2010102244A1 (en) * 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
PT2488554T (pt) * 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
WO2011123819A2 (en) * 2010-04-01 2011-10-06 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of multiple myeloma
EP2582388A4 (en) * 2010-06-18 2014-04-16 Kalobios Pharmaceuticals Inc IDENTIFYING EPHA3 AS A MARKER FOR THE PRESENCE OF A SOLID TUMOR
TWI655210B (zh) * 2010-12-08 2019-04-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2741774A4 (en) * 2011-08-12 2015-05-20 Kalobios Pharmaceuticals Inc METHOD FOR THE TREATMENT OF HEMATOLOGIC PROLIFERATIVE DISEASES BY TARGETING EPHA3 EXPRESSED ON ABERRANT VACCINATION SYSTEM IN THE BONE MARROW
US9975942B2 (en) 2013-11-11 2018-05-22 Wake Forest University Health Services EPHA3 And multi-valent targeting of tumors
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
IL291937A (en) * 2019-10-09 2022-06-01 Council Queensland Inst Medical Res Direct link to epha3 and its uses

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1508337A3 (en) 1998-11-20 2006-04-19 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1163339A1 (en) 1999-04-01 2001-12-19 Innogenetics N.V. A polypeptide structure for use as a scaffold
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
US6652853B2 (en) * 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20050049194A1 (en) * 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2339004B1 (en) 2002-03-19 2015-02-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
AU2003232457A1 (en) 2002-05-29 2003-12-19 Curagen Corporation Compositions and methods of use for an ephrin rreceptor
WO2004028551A1 (en) * 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2006047639A2 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP2343380B1 (en) * 2004-11-16 2019-06-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
ES2395842T3 (es) 2006-01-17 2013-02-15 Synthon Biopharmaceuticals B.V. Composiciones y métodos para la humanización y optimización de N-glicanos en plantas
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies

Also Published As

Publication number Publication date
US20080286272A1 (en) 2008-11-20
AU2008226905A1 (en) 2008-09-18
PL3199180T3 (pl) 2022-08-08
US8637016B2 (en) 2014-01-28
EP2136838A2 (en) 2009-12-30
CN101641115B (zh) 2013-04-24
JP2010520290A (ja) 2010-06-10
EP2136838B1 (en) 2017-03-08
CN101641115A (zh) 2010-02-03
WO2008112192A3 (en) 2008-11-13
JP5311060B2 (ja) 2013-10-09
PT3199180T (pt) 2022-04-01
DK3199180T3 (da) 2022-03-21
CA2679986A1 (en) 2008-09-18
IL200764A (en) 2017-01-31
IL200764A0 (en) 2010-05-17
NZ579478A (en) 2012-08-31
EP3199180B1 (en) 2022-01-05
ES2910298T3 (es) 2022-05-12
EP3199180A1 (en) 2017-08-02
WO2008112192A2 (en) 2008-09-18
AU2008226905B2 (en) 2014-05-01
AU2008226905C1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
AU2008226905C1 (en) EphA3 antibodies for the treatment of solid tumors
JP5876728B2 (ja) ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法
JP2013508292A (ja) ＥｐｈＡ３に対する抗体
US20190270821A1 (en) Epha3 antibodies for the treatment of pulmonary fibrosis
AU2011235867B2 (en) EphA3 antibodies for the treatment of multiple myeloma
HK1242185A1 (en) Epha3 antibodies for the treatment of solid tumors
HK1242185B (en) Epha3 antibodies for the treatment of solid tumors
US9109032B2 (en) Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130304

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421